Phuturdex › Diseases › Kidney neoplasm
Drugs in development · updated 30 October 2026
Kidney neoplasm: drugs in development
As of 30 October 2026 there are 77 active clinical trials (recruiting or ongoing, phases I–III) on 92 drugs for kidney neoplasm. 48 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
Sorted by most advanced phase and number of active trials. Showing 40 of 48 drugs.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| IpilimumabYERVOY, ipililumab IV | III | 11 | NCT06364631 |
| PembrolizumabKEYTRUDA, MK-3475 | III | 10 | NCT06364631 |
| CabozantinibResniben®, Cabometyx® | III | 9 | NCT07011719 |
| NivolumabOpdivo, ONO-4538 | III | 9 | NCT06364631 |
| AxitinibInlyta®, Axitinib Accord® | III | 6 | NCT06726421 |
| BelzutifanWelireg® | III | 6 | NCT04195750 |
| LenvatinibLenvatinib Mesilate Capsules, Levatinib | III | 6 | NCT06726421 |
| EverolimusRAD001, Everoliumus | III | 3 | NCT04195750 |
| PazopanibVotrient® | III | 2 | NCT06726421 |
| SunitinibSutent®, Sunitinib Accord® | III | 2 | NCT03091192 |
| AtorvastatinLipitor, Atorvaliq® | III | 1 | NCT05796973 |
| BupivacaineExparel, Bupivacain | III | 1 | NCT06349668 |
| LidocaineXylocaine, Bondlido® | III | 1 | NCT06349668 |
| MorphineArymo Er®, Morphabond Er® | III | 1 | NCT06349668 |
| AtezolizumabTecentriq, MPDL3280A | I–II | 3 | NCT05944237 |
Sorted by most advanced phase and number of active trials. Showing 15 of 44 drugs.
All 92 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Renal cell carcinoma 228 drugs
- Non-small-cell lung carcinoma 726 drugs
- Melanoma 352 drugs
- Head and neck squamous cell carcinoma 321 drugs
- Colorectal neoplasm 534 drugs
- Transitional cell carcinoma 146 drugs
- Metastasis 493 drugs
- Hepatocellular carcinoma 266 drugs
- Sarcoma 204 drugs
- Wilms Tumor 37 drugs
- Ovarian neoplasm 411 drugs
- Triple-negative breast neoplasm 334 drugs
Broader categories
- Urologic Diseases 16 drugs
- Female urogenital disease 11 drugs
- Female urogenital diseases and pregnancy complications 3 drugs
- Urogenital Diseases 16 drugs
- Male urogenital disease 19 drugs
- Kidney disease 38 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D007680 “Kidney Neoplasms”.